■烟酰胺腺嘌呤二核苷酸(NAD)是一种辅酶,在几种代谢过程中起着至关重要的作用。本研究探讨了成人烟酰胺腺嘌呤二核苷酸(NAD)水平与代谢疾病(MD)的关系。
■在这项横断面研究中,所有数据均来自冀东社区.MD被定义为存在以下一种或多种疾病成分:高血压,血脂异常,糖尿病,高尿酸血症,肥胖,和非酒精性脂肪性肝病(NAFLD)。MD组件分为三组:具有一个组件的组件,那些有两个组成部分的,和那些有三到六个组件的。使用循环测定和LC-MS/MS分析测量全血NAD+水平。参与者根据其NAD+水平四分位数分为四组。使用多变量逻辑回归评估全血NAD水平与MD的相关性。
■在1,394名合格参与者中,平均年龄43.2岁,74.3%有MD。在NAD+的前四分位数中,MD及其各组成部分的患病率(高血压,高脂血症,糖尿病,高尿酸血症,肥胖,和NAFLD)为87.9%35.2%,62.3%,8.7%,36.9%,21.0%,60.5%,分别。与最低NAD+四分位数(≤29.4μmol/L)相比,MD的最高四分位数的调整后比值比和95%置信区间为3.01(1.87-4.87),2.48(1.44-4.29)对于1个MD组件,2个MD组件为2.74(1.45-5.17),3-6个MD组件为4.30(2.32-7.98)。在NAD+水平为31.0μmol/L时,MD的风险开始增加,正如NAD+水平与MD的梯度关联所揭示的。年龄之间没有显著的交互作用,性别,饮酒,吸烟,MD的NAD+(相互作用≥0.10的p)。
■NAD+增加与MD显著相关,以及它的各个组成部分。我们的发现为血液NAD水平与MD之间的关系提供了新的证据。
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme and plays a crucial role in several metabolic processes. This
study explored the association of nicotinamide adenine dinucleotide (NAD+) levels with metabolic disease (MD) in adults.
In this cross-sectional
study, all data were collected from the Jidong community. MD was defined as the presence of one or more of the following disease components: hypertension, dyslipidemia, diabetes, hyperuricemia, obesity, and non-alcoholic fatty liver disease (NAFLD). The MD components were categorized into three groups: those with one component, those with two components, and those with three to six components. The whole blood NAD+ level was measured using a cycling assay and LC-MS/MS analysis. The participants were divided into four groups based on their NAD+ level quartiles. Multivariable logistic regression was used to evaluate the association of the whole blood NAD+ levels with MD.
Of the 1,394 eligible participants, the average age was 43.2 years, and 74.3% had MD. In the top quartile of NAD+, the prevalence of MD and each of its components (hypertension, hyperlipidemia, diabetes, hyperuricemia, obesity, and NAFLD) were 87.9% 35.2%, 62.3%, 8.7%, 36.9%, 21.0%, and 60.5%, respectively. As compared with the lowest NAD+ quartile (≤29.4 μmol/L), the adjusted odds ratios and 95% confidence interval of the highest quartile were 3.01 (1.87-4.87) for MD, 2.48 (1.44-4.29) for 1 MD component, 2.74 (1.45-5.17) for 2 MD components, and 4.30 (2.32-7.98) for 3-6 MD components. The risk of MD began to increase at NAD+ levels of 31.0 μmol/L, as revealed by the gradient associations of NAD+ levels with MD. There was no significant interaction between age, sex, drinking, smoking, and NAD+ for MD (p for interaction ≥0.10).
Increased NAD+ was significantly associated with MD, as well as its individual components. Our findings provide new evidence for the relationship between blood NAD+ levels and MD.